Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W

Baird R W upgraded shares of Contineum Therapeutics (NASDAQ:CTNM - Free Report) to a strong-buy rating in a report issued on Tuesday morning, Zacks.com reports.

CTNM has been the subject of a number of other research reports. Robert W. Baird began coverage on Contineum Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $32.00 price target for the company. Royal Bank of Canada upped their price objective on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Wednesday, August 14th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $29.50.

Contineum Therapeutics Trading Down 0.1 %

NASDAQ CTNM traded down $0.02 on Tuesday, hitting $16.26. 77,533 shares of the stock traded hands, compared to its average volume of 79,370. The stock has a 50-day moving average of $17.98 and a 200 day moving average of $17.64. Contineum Therapeutics has a twelve month low of $13.27 and a twelve month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). On average, analysts anticipate that Contineum Therapeutics will post -2.04 earnings per share for the current fiscal year.

Institutional Trading of Contineum Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sandia Investment Management LP purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter worth about $88,000. Rhumbline Advisers acquired a new stake in Contineum Therapeutics in the 2nd quarter worth approximately $118,000. Bank of New York Mellon Corp acquired a new position in Contineum Therapeutics in the 2nd quarter valued at $356,000. Driehaus Capital Management LLC acquired a new position in Contineum Therapeutics during the 2nd quarter worth $1,174,000. Finally, Squarepoint Ops LLC bought a new position in shares of Contineum Therapeutics in the second quarter worth about $2,642,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).